Neutropenic Sepsis in the Emergency Department: Essential FRCEM SBA Practice Questions Explained

Neutropenic sepsis sits at the intersection of oncology, infectious disease, and emergency medicine — and it is precisely the kind of complex, time-critical presentation that the FRCEM SBA exam uses to probe whether candidates can synthesise clinical reasoning under pressure. With chemotherapy now routinely delivered in community and day-unit settings across the NHS, UK emergency departments are seeing more patients presenting febrile and immunocompromised than ever before. Missing or delaying the diagnosis carries a mortality risk that is both clinically and medicolegally serious. Performing well on FRCEM SBA practice questions about this topic requires more than memorising a drug name — it demands a working understanding of the pathophysiology, a command of NICE Guideline CG151, and an appreciation of the specific traps examiners set for unwary candidates.

Definition, Epidemiology, and Why This Matters in the ED

NICE CG151 defines neutropenic sepsis as a neutrophil count below 0.5 x 10⁹/L (or below 1.0 x 10⁹/L with an anticipated further decline) combined with a temperature exceeding 38°C, or other clinical features consistent with sepsis in the absence of fever. It is the most common cause of treatment-related mortality in patients receiving anticancer therapy, complicating approximately 5–8% of all chemotherapy cycles. As the volume of patients receiving cytotoxic therapy in community oncology units grows, the emergency department has become the frontline for recognising and managing this emergency.

The highest-risk groups are those receiving intensive myelosuppressive regimens for acute leukaemia, high-grade lymphoma, and patients who have undergone haematopoietic stem cell transplantation (HSCT). The neutrophil nadir characteristically occurs 7–14 days after a chemotherapy cycle, depending on the agent used — a detail that frequently appears in FRCEM SBA clinical scenarios. Fluorouracil, anthracyclines, platinum agents, taxanes, and alkylating agents are the most commonly implicated cytotoxics. Beyond chemotherapy, neutropenia can arise from marrow infiltration by haematological malignancy, aplastic anaemia, immunosuppressive agents such as azathioprine or methotrexate, and drug-induced agranulocytosis — clozapine and carbimazole being classic emergency medicine examples.

Pathophysiology: Why Classical Signs Fail

Understanding the pathophysiology is not merely academic — it is the key to answering the most discriminating FRCEM SBA exam questions on this topic, which often hinge on recognising that standard clinical signs are unreliable in the neutropenic patient.

Neutrophils are the primary cellular effectors of early innate immunity against bacterial and fungal pathogens. When the absolute neutrophil count falls below 0.5 x 10⁹/L, the host loses the ability to generate a meaningful localised inflammatory response. Pus formation requires neutrophil accumulation at the site of infection; in severe neutropenia, this does not occur. Consequently, the classic features of pneumonia (consolidation and productive cough), urinary tract infection (pyuria), cellulitis (frank fluctuance), and intra-abdominal sepsis (peritonism) are frequently absent or profoundly attenuated. Chest radiographs may appear deceptively normal early in pneumonia. Urine may remain clear despite bacteriuria. Inflammatory markers including CRP and white cell count lose diagnostic specificity in this context — a neutrophilic leucocytosis, by definition, cannot occur.

The microbiological landscape is also distinctive. Gram-negative bacilli — Escherichia coli, Klebsiella species, and Pseudomonas aeruginosa — account for the majority of bacteraemic episodes and carry the highest immediate mortality risk. Gram-positive organisms including Staphylococcus aureus, coagulase-negative staphylococci (associated with central venous catheters), and viridans streptococci are also prevalent. Critically, a microbiological source is identified in only 20–30% of episodes, meaning the empirical antibiotic decision is made without microbiological confirmation in the vast majority of cases. In prolonged neutropenia exceeding 7 days, or following HSCT, invasive fungal infection from Candida and Aspergillus species becomes a significant and potentially fatal concern.

ED Assessment and Management: The NICE CG151 Framework

History and Examination

Every patient presenting with fever who has received chemotherapy within the preceding 6 weeks should be assessed for neutropenic sepsis until proven otherwise. Key historical elements include the chemotherapy regimen and cycle timing (to estimate nadir risk), any prophylactic antibiotic use (which may modify fever and mask bacteraemia), the presence of an indwelling central venous catheter (CVC), and the underlying malignancy. Examination should systematically evaluate all potential foci — oral cavity, perianal area, skin and catheter entry sites — bearing in mind that classical signs may be absent.

Investigations

The priority investigations are full blood count with differential (to confirm neutropenia), blood cultures — minimum two sets, one peripheral and one from each lumen of any CVC — chest radiograph, urine culture, CRP, U&Es, LFTs, lactate, and coagulation screen. Procalcitonin, while not mandated by NICE CG151, is increasingly used in clinical practice as a marker of bacterial sepsis severity and therapeutic response. CT imaging of chest, abdomen, and pelvis may be required to identify occult foci, particularly neutropenic enterocolitis (typhlitis), which presents with right iliac fossa pain, diarrhoea, and CT evidence of caecal wall thickening.

The One-Hour Antibiotic Standard

NICE CG151 is unequivocal: empirical broad-spectrum antibiotics must be administered within one hour of presentation. This is the single most important management principle and the one most frequently tested in FRCEM SBA practice questions. The recommended first-line agent is an antipseudomonal beta-lactam — piperacillin-tazobactam (Tazocin) is the standard choice across most UK trusts, though local antibiotic stewardship policies and resistance patterns govern final prescribing decisions. Meropenem is reserved for patients with known resistant organisms, recent broad-spectrum exposure, or severe sepsis/septic shock where the risk of treatment failure is unacceptable. The British National Formulary provides current dosing guidance, but the emergency physician must be familiar with standard empirical doses — piperacillin-tazobactam 4.5 g IV eight-hourly in adults with normal renal function.

Vancomycin (or teicoplanin) is not added routinely but is indicated where there is clinical suspicion of catheter-related infection, skin or soft tissue infection, known MRSA colonisation, or haemodynamic instability. Anti-fungal therapy with an echinocandin (caspofungin) or liposomal amphotericin B is initiated after 4–7 days of persistent fever despite adequate antibacterial therapy, or immediately in high-risk patients with suspected invasive fungal disease.

Risk Stratification: The MASCC Score

The Multinational Association for Supportive Care in Cancer (MASCC) score is the validated risk stratification tool endorsed by NICE CG151 for guiding disposition. Variables include burden of illness, absence of hypotension, absence of COPD, solid tumour or haematological malignancy without previous fungal infection, outpatient status, absence of dehydration, and age below 60. A score of 21 or above identifies patients as low risk, with a complication rate below 10% and a mortality below 1%. Low-risk patients may be candidates for oral antibiotic therapy (commonly ciprofloxacin plus co-amoxiclav) and early discharge with robust safety-netting, following senior oncology or haematology discussion. High-risk patients (MASCC below 21) require inpatient management, and those with septic shock, respiratory failure, or organ dysfunction require critical care escalation.

How the FRCEM SBA Exam Tests This Topic

The FRCEM SBA exam maps to the RCEM curriculum, which includes oncological emergencies as a core presentation. Questions on neutropenic sepsis typically test one of several concepts: the definition and diagnostic threshold (neutrophil count, temperature criterion), the correct first-line antibiotic and the one-hour window, the MASCC score and its clinical application, recognition of attenuated signs leading to anchoring on an incorrect diagnosis, and the management of specific complications such as neutropenic enterocolitis or suspected catheter-related bloodstream infection.

A common question stem presents a patient who received CHOP chemotherapy 10 days ago, now presenting with a temperature of 38.2°C, heart rate 112 bpm, and a neutrophil count of 0.3 x 10⁹/L. The question asks what the single best next action is. Distractor options typically include sending blood cultures and waiting for results, administering paracetamol and reassessing, or starting oral antibiotics. The correct answer is IV piperacillin-tazobactam immediately — because the one-hour rule is non-negotiable and cultures should never delay antibiotics.

Another high-yield stem involves a post-HSCT patient with 12 days of profound neutropenia and persistent fever despite 5 days of piperacillin-tazobactam, with a new pulmonary infiltrate on CT. The question tests recognition that invasive aspergillosis must now be considered and antifungal therapy initiated. Candidates who focus solely on antibacterial escalation lose marks here. For targeted FRCEM SBA revision on oncological emergencies and related immunological presentations, the FRCEM Single Best Answer revision course at EM Learning Centre includes structured question banks with detailed explanations mapped to the RCEM curriculum.

Revision Pearls: High-Yield Facts for the Exam

1. Neutropenic sepsis is defined by a neutrophil count below 0.5 x 10⁹/L (or below 1.0 x 10⁹/L with anticipated fall) plus fever above 38°C or systemic features of sepsis — per NICE CG151.
2. Empirical antibiotics must be given within one hour. This is the most tested management principle. Nothing delays this — not pending cultures, not uncertainty about the source.
3. Classical signs of localised infection are attenuated or absent because neutrophils cannot accumulate at the site of infection. Diagnose on systemic criteria.
4. MASCC score 21 or above = low risk. Below 21 = high risk requiring inpatient IV antibiotics. The score is the disposition tool endorsed by NICE.
5. Chemotherapy nadir occurs 7–14 days post-cycle. A patient presenting on day 10 after CHOP is in the highest-risk window.
6. Neutropenic enterocolitis (typhlitis) presents with RIF pain, diarrhoea, and caecal wall thickening on CT. It is a surgical emergency in the neutropenic patient and carries high mortality.
7. G-CSF (filgrastim) is used prophylactically in high-risk regimens but is not routinely recommended in established neutropenic sepsis — this distinction frequently appears in MRCEM SBA practice questions.
8. Fungal cover should be added after 4–7 days of unresponsive fever, or immediately in post-HSCT patients or those with CT evidence of pulmonary fungal disease.

Common Pitfalls: Where Candidates Lose Marks

• Delaying antibiotics to await blood culture results. The one-hour rule is absolute. Cultures are taken simultaneously, not sequentially.
• Anchoring on a normal-appearing examination. The absence of localising signs does not exclude serious infection — it is expected in this population.
• Omitting the MASCC score. Candidates who default to blanket admission without applying risk stratification miss the nuance the examiner is testing.
• Confusing neutropenic sepsis with febrile neutropenia in a stable patient. Not all neutropenic patients with fever have sepsis, but all must be treated as such until the MASCC score and clinical course clarify the risk.
• Adding vancomycin routinely. It is indicated only for specific indications (CVC infection, MRSA risk, haemodynamic compromise) — routine addition is incorrect and tested as a distractor.
• Failing to escalate to oncology/haematology. The emergency physician initiates management; specialist input for ongoing management is mandatory and is expected in management questions.

How EM Learning Centre Supports Your FRCEM Single Best Answer Revision

Neutropenic sepsis is one of many high-stakes oncological and critical care presentations that the FRCEM SBA exam tests with increasing sophistication. Preparing effectively means working through well-constructed, curriculum-mapped FRCEM SBA practice questions with detailed explanations — not simply reading guidelines in isolation. The EM Learning Centre provides a structured FRCEM SBA revision course built around the current RCEM curriculum, with question banks covering oncological emergencies, critical care, toxicology, paediatrics, trauma, and the full breadth of FRCEM SBA clinical scenarios. Each question includes a referenced explanation so you understand not just the correct answer, but why the distractors are wrong — the level of discrimination that separates passing from failing candidates.

Whether you are beginning your FRCEM SBA exam preparation or refining your performance in the final weeks before sitting, targeted practice with expert commentary is the most evidence-based approach to improving your score. Visit the EM Learning Centre homepage to explore the full range of FRCEM SBA online revision resources available to support your journey to fellowship.

References

1. National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management in people with cancer. Clinical Guideline CG151. 2012. NICE (nice.org.uk)
2. National Institute for Health and Care Excellence. British National Formulary: Piperacillin with tazobactam. British National Formulary (bnf.nice.org.uk)
3. Royal College of Emergency Medicine. RCEM Curriculum and Competency Framework. Royal College of Emergency Medicine (rcem.ac.uk)
4. Klastersky J, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology. 2000. Referenced via NICE CG151 evidence base (nice.org.uk)
5. NHS England. Sepsis guidance and clinical tools. NHS (nhs.uk)